Source-grounded facts extracted from SPRUCE BIOSCIENCES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
SPRUCE BIOSCIENCES, INC. shareholders approved Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation at the 2026-05-21 meeting.
“Proposal 4: Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation. The Company’s stockholders indicated, on an advisory basis, their preference for the Company to hold a stockholder advisory vote on the compensation of the Company’s named executive officers every year.”
SPRUCE BIOSCIENCES, INC. shareholders approved Advisory Vote on the Compensation of the Company’s Named Executive Officers at the 2026-05-21 meeting.
“Proposal 3: Advisory Vote on the Compensation of the Company’s Named Executive Officers. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on April 9, 2026.”
SPRUCE BIOSCIENCES, INC. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2026-05-21 meeting.
“Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the selection by the Audit Committee of the Board of Directors of BDO USA, P.C. as the independent registered public accounting firm of the Company for the Company’s fiscal year ending December 31, 2026.”
SPRUCE BIOSCIENCES, INC. shareholders approved Election of Class III Directors at the 2026-05-21 meeting.
“Proposal 1: Election of Class III Directors. The Company’s stockholders elected each of the three nominees named below to serve as Class III directors of the Company until the Company’s 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal.”
SPRUCE BIOSCIENCES, INC. reported preliminary financial results for the first quarter ended March 31, 2026.
“On May 13, 2026, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026 and providing corporate updates.”
SPRUCE BIOSCIENCES, INC. entered into Underwriting Agreement with Leerink Partners LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc. valued at $69.0 million (effective 2026-04-20).
“On April 20, 2026, Spruce Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc., as representatives of the several underwriters listed therein”
SPRUCE BIOSCIENCES, INC. terminated Collaboration Agreement with Kaken Pharmaceutical Co., Ltd. (effective 2026-03-31).
“On March 16, 2026, Spruce Biosciences, Inc. (the “Company”) entered into a Termination Agreement (the “Termination Agreement”) with Kaken Pharmaceutical Co., Ltd. (“Kaken”) to terminate by mutual agreement that certain Collaboration and License Agreement, dated as of January 5, 2023, by and between the Company and Kaken (the “Collaboration Agreement”). The Collaboration Agreement will terminate effective as of March 31, 2026 (the “Termination Date”) pursuant to the Termination Agreement, and from and after the Termination Date, the Collaboration Agreement is of no further force or effect except as otherwise expressly set forth in such agreement.”
SPRUCE BIOSCIENCES, INC. reported the year ended December 31, 2025 results: net income $3.
“Net loss for the year ended December 31, 2025 was $3”
SPRUCE BIOSCIENCES, INC. terminated Prior Sales Agreement with Jefferies LLC (effective 2026-03-09).
“(the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Jefferies as its sales agent and/or principal, shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering amount not exceeding the Maximum Program Amount, as such term is defined in the Sales Agreement.”
SPRUCE BIOSCIENCES, INC. entered into Open Market Sale Agreement with Jefferies LLC (effective 2026-03-09).
“On March 9, 2026, Spruce Biosciences, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”).”
SPRUCE BIOSCIENCES, INC. issued common stock to Avenue Capital Management II, L.P. (as Agent) for up to $4.0 million of the outstanding principal.
“the Lender will have the right to convert up to $4.0 million of the outstanding principal of the Loans (the “Conversion Option”) at a price per share equal to 120% of the exercise price of the Warrant”
SPRUCE BIOSCIENCES, INC. issued warrant to Avenue Venture Opportunities Fund II, L.P. for up to $3,200,000 worth of shares.
“the Company will issue to the Lender a warrant (the “Warrant”) to purchase up to $3,200,000 worth of shares of the Company’s common stock”
SPRUCE BIOSCIENCES, INC. entered into Loan and Security Agreement with Avenue Capital Management II, L.P. and Avenue Venture Opportunities Fund II, L.P. valued at $50.0 million (effective 2026-01-07).
“On January 7, 2026 (the “Closing Date”), Spruce Biosciences, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan and Security Agreement”) and a Supplement to the Loan and Security Agreement (together with the Loan and Security Agreement, the “Loan Agreement”), with Avenue Capital Management II, L.P., as administrative agent and collateral agent (the “Agent”) and Avenue Venture Opportunities Fund II, L.P., as lender (the “Lender”).”
SPRUCE BIOSCIENCES, INC. incurred credit facility of up to $50.0 million with Avenue Venture Opportunities Fund II, L.P., as lender at the greater of (x) the sum of 5.25% plus the prime rate...and (y) 12.25% maturing July 1, 2029.
“with Avenue Capital Management II, L.P., as administrative agent and collateral agent (the “Agent”) and Avenue Venture Opportunities Fund II, L.P., as lender (the “Lender”). The Loan Agreement makes available to the Company term loans in an aggregate principal amount of up to $50.0 million”
SPRUCE BIOSCIENCES, INC. issued pre-funded warrants to purchase up to 233,144 shares of Common Stock of warrant to certain institutional investors for purchase price for the Pre-Funded Warrants is $67.99.
“up to 233,144 shares of Common Stock (the “Pre-Funded Warrants”) in a private placement transaction (the “Private Placement”). The purchase price per share of Common Stock is $68.00 per share (the “Purchase Price”) and the purchase price for the Pre-Funded Warrants is $67.99, which equals the Purchase Price minus the $0.01 exercise price per Pre-Funded”
SPRUCE BIOSCIENCES, INC. issued 502,181 shares of common stock to certain institutional investors for $68.00 per share.
“up to 233,144 shares of Common Stock (the “Pre-Funded Warrants”) in a private placement transaction (the “Private Placement”). The purchase price per share of Common Stock is $68.00 per share (the “Purchase Price”) and the purchase price for the Pre-Funded Warrants is $67.99, which equals the Purchase Price minus the $0.01 exercise price per Pre-Funded”
SPRUCE BIOSCIENCES, INC.: Amendment to Certificate of Incorporation to effect a 1-for-75 reverse stock split (effective 2025-08-04).
“On July 23, 2025, Spruce Biosciences, Inc., a Delaware corporation (the “Company”), filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), to effect a one-for-seventy-five (1:75) reverse stock split of its outstanding common stock, effective as of August 4, 2025 (the “Reverse Stock Split”).”
SPRUCE BIOSCIENCES, INC.: Filed Certificate of Designation for Series A Preferred Stock, establishing preferences, rights, and limitations including 22,000,000 votes limited to voting on a Reverse Stock Split Proposal, non-convertibility, $100.00 liquidation preference, transfer restrictions, and redemption provisions (effective 2025-05-28).
“On May 28, 2025, in connection with the Purchase Agreement, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Preferred Stock (the “Series A Certificate of Designation”) with the Secretary of State of the State of Delaware.”
SPRUCE BIOSCIENCES, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5815(a)(1)(B)(ii)(d), 5810(c)(3)(A)(ii), 5800).
“pects that Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. The Company has appealed Nasdaq’s determination to its Hearings Panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. However, pursuant to Nasdaq Listing Rule 5815(a)(1)(B)(ii)(d), a timely request for a hearing will not stay the trading suspension of the Company’s common stock as the Company was afforded the second 180 days compliance period described in Nasdaq Listing Rule 5810(c)(3)(A)(ii) and”
SPRUCE BIOSCIENCES, INC. announced a restructuring with charges of approximately $0.9 million (workforce reduction of 55%).
“and expenditures relating to the workforce reduction will not be known until all related activities have been completed. The Company estimates that it will incur approximately $0.9 million in cash charges in connection with the workforce reduction, consisting of expenses related to severance payments and healthcare coverage assistance and related costs. The Company”
SPRUCE BIOSCIENCES, INC. reported financial results for first quarter ended March 31, 2024.
“Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2024 and provided corporate updates.”
SPRUCE BIOSCIENCES, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).
“April 26, 2024, Spruce Biosciences, Inc. (the “ Company ”) received a notice from The Nasdaq Global Select Market (“ Nasdaq ”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Select Market. The Company has 180 calendar days, or until October 23, 2024, to regain compliance with the minimum bid price requirement. To”
SPRUCE BIOSCIENCES, INC. reported full year ended December 31, 2023 results: revenue $10.1 million, net income $47.9 million.
“topline results from CAHmelia-204 and additional dose-ranging data from CAHptain-205. • Collaboration Revenue: Collaboration revenue for the year ended December 31, 2023 was $10.1 million compared to nil in 2022, reflecting the partial recognition of the $15.0 million upfront payment received from Kaken Pharmaceutical (“Kaken”) in connection with the company’s”
SPRUCE BIOSCIENCES, INC. announced a restructuring with charges of the Company estimates that it will incur approximately $0.4 million in cash charges in connection with the Realignment Plan, consisting of expenses related to e affecting workforce reduction of approximately 21% (workforce reduction of approximately 21%).
“and expenditures relating to the Realignment Plan will not be known until all related activities have been completed. The Company estimates that it will incur approximately $0.4 million in cash charges in connection with the Realignment Plan, consisting of expenses related to employee severance payments and healthcare coverage assistance and related costs. The”
SPRUCE BIOSCIENCES, INC. reported the third quarter ended September 30, 2023 results: net income $12.4 million.
“Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates”
SPRUCE BIOSCIENCES, INC. reported second quarter ended June 30, 2023 results: revenue $2.2 million.
“to fund operating and capital expenditures into the first half of 2025. • Collaboration Revenue: Collaboration revenue for the three and six months ended June 30, 2023 were $2.2 million and $4.1 million, respectively, compared to nil for the same periods in 2022. The increase in collaboration revenue reflects the partial recognition of the $15.0 million upfront”
SPRUCE BIOSCIENCES, INC. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2023-05-25 meeting.
“Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
SPRUCE BIOSCIENCES, INC. shareholders approved Election of Directors at the 2023-05-25 meeting.
“Proposal 1. Election of Directors The Company’s stockholders elected the three persons listed below as Class III Directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Percival Barretto-Ko was appointed as Class II Director at SPRUCE BIOSCIENCES, INC..
“On May 23, 2023, the Board appointed Percival Barretto-Ko to the Board, to fill the vacancy resulting from Dr. Chaya's resignation, contingent upon Dr. Chaya's resignation and effective as of the Effective Date.”
Dina Chaya resigned as Director at SPRUCE BIOSCIENCES, INC..
“On May 22, 2023, Dina Chaya, Ph.D., C.F.A., notified the board of directors (the “Board”) of Spruce Biosciences, Inc. (the “Company”) of her resignation as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”) and the Audit Committee of the Board (the “Audit Committee”), effective as of May 25, 2023 (the “Effective Date”).”
SPRUCE BIOSCIENCES, INC. reported financial results for the quarter ended March 31, 2023.
“On May 15, 2023, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2023 and providing corporate updates.”
SPRUCE BIOSCIENCES, INC. reported the year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022 was $46.2 million compared to $42.3 million in 2021..
“Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the full year ended December 31, 2022 and providing corporate updates.”
SPRUCE BIOSCIENCES, INC. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $53.6 million (effective 2023-02-08).
“On February 8, 2023, Spruce Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue (i) 16,116,000 shares of the Company’s common stock (“Common Stock”), (ii) pre-funded warrants to purchase 800,000 shares of Common Stock (the “Pre-Funded Warrants”) to a Purchaser and (iii) 12,687,000 warrants to purchase Common Stock (the “Standard Warrants” and together with the Pre-Funded Warrants, the “Warrants”) in a private placement transaction (the “Private Placement”).”
SPRUCE BIOSCIENCES, INC. entered into Collaboration and License Agreement with Kaken Pharmaceutical Co., LTD. valued at $15.0 million (effective 2023-01-05).
“On January 5, 2023, Spruce Biosciences, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Agreement”) with Kaken Pharmaceutical Co., LTD. (“Kaken”).”
SPRUCE BIOSCIENCES, INC. terminated Lease Termination Agreement with BP3-SF7 2001 JS OWNER LLC valued at a termination fee of $0.6 million (effective 2022-11-28).
“On November 28, 2022, the Company entered into a Lease Termination Agreement (the “Lease Termination Agreement”) with BP3-SF7 2001 JS OWNER LLC (the “Landlord”) to terminate that certain Office Lease Agreement, dated as of February 13, 2020, by and between the Company and the Landlord (as successor-in-interest to DC Station Owner, LLC) (the “Prior Lease”) for certain premises located at 2001 Junipero Serra Boulevard, Suite 640, Daily City, California 94014.”
SPRUCE BIOSCIENCES, INC. entered into New Lease with 611 Gateway Center LP valued at approximately $0.3 million (effective 2022-12-01).
“On December 1, 2022, Spruce Biosciences, Inc. (the “Company”) entered into a lease agreement (the “New Lease”) with 611 Gateway Center LP for the lease of 6,496 square feet of office space located at 611 Gateway Boulevard, Suite 740, South San Francisco, California 94080, for the Company’s principal executive offices.”
SPRUCE BIOSCIENCES, INC. reported the third quarter ended September 30, 2022 results: net income $11.4 million.
“Net loss for the three and nine months ended September 30, 2022 was $11.4 million and $35.0 million, respectively, compared to $11.4 million and $33.1 million, respectively, for the same periods in 2021.”
Michael Grey changed role as Interim Chief Executive Officer at SPRUCE BIOSCIENCES, INC..
“Dr. Szwarcberg will succeed Michael Grey, who had served as the Company’s Interim Chief Executive Officer since November 15, 2021, and who will continue to hold his position as Executive Chairman of the Board.”
Javier Szwarcberg was appointed as Class III director at SPRUCE BIOSCIENCES, INC..
“the Board also appointed Dr. Szwarcberg as a member of the Board effective as of the Start Date.”
Javier Szwarcberg was appointed as Chief Executive Officer at SPRUCE BIOSCIENCES, INC..
“appointed Javier Szwarcberg, M.D., MPH, as the Company’s Chief Executive Officer, effective January 3, 2022”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.